Clinical Trials Browser

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07389616 2026-02-05

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Phase 2/3 Recruiting

40 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Phase 1 Completed

26 enrolled 24 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Phase 1/2 Recruiting

250 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT07081607 2025-07-23

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Phase 2 Not yet recruiting

30 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT05958719 2024-12-30

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Phase 2 Recruiting

37 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06176027 2024-10-29

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

Phase 1/2 Recruiting

52 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03542266 2023-08-22

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Phase 2 Completed

21 enrolled 11 charts

Lymphoid

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT05182957 2023-01-31

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 2 Unknown

40 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Phase 1/2 Unknown

116 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04480125 2022-04-20

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Phase 2 Unknown

28 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04052659 2021-03-09

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Phase 2 Unknown

30 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01129180 2013-12-03

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Phase 1 Completed

8 enrolled

DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Leukemia, Prolymphocytic, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Leukemia, Large Granular Lymphocytic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Clinical Trials

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma